Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) saw an upside of 12.98% to close Monday at $5.31 after adding $0.61 on the day. The 5-day average trading volume is 2,149,800 shares of the company’s common stock. It has gained $5.41 in the past week. An average of 25,567,084 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 10,369,586.
CRVS’s 1-month performance is 114.11% or $2.83 on its low of $2.21 reached on 09/14/21. The company’s shares have touched a 52-week low of $1.86 and high of $9.54, with the stock’s rally to the 52-week high happening on 09/21/21. YTD, CRVS has achieved 49.16% or $1.75. However, the current price is down -44.34%% from the 52-week high price.
A Backdoor Way To Profit From Today’s Crypto Bull Market
In any crypto bull market, there's a lot of money to be made.
But what if we told you the best opportunities are not cryptocurrencies themselves… but instead, simply crypto stocks?
This strategy is simply and ridiculously easy.
Here are 6 ways to gain exposure to crypto outside the norm. This is arguably the safest bet you can make.
On Oct 01, 11 days have gone by since the last insider trading activity for Corvus Pharmaceuticals Inc. (CRVS). EcoR1 Capital, LLC (10% Owner) most recently sold 2,000,000 shares at $4.96 per share on Oct 01. This transaction cost the insider $9,928,800. 10% Owner, EcoR1 Capital, LLC, sold 3,000,000 shares at a price of $5.04 on Sep 30. Then, on Sep 20, Director ORBIMED ADVISORS LLC sold 1,109,644 shares at a price of $6.09 per share. This transaction amounted to $6,757,732.
Corvus Pharmaceuticals Inc. (CRVS) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.24 for the sector.CRVS stock has a beta of 0.99. Moving on to other valuation ratios, the price-to-book (PB) in the most recent quarter is 2.33.
Corvus Pharmaceuticals Inc.’s quick ratio for the period ended June 29 was 5.60, with the current ratio over the same period at 5.60 meaning that CRVS stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.00, while the total debt to equity was 0.00.
For the quarterly period ending June 29 this year, Corvus Pharmaceuticals Inc.’s cash and short-term investments amounted to $7.55 million against total debt of $1.78 million. Analysts expected CRVS to announce -$0.32 per share in earnings in its latest quarter, but it posted -$0.28, representing a 12.50% surprise. CRVS stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 12.99 million, with total debt at $1.78 million. Shareholders hold equity totaling $42.42 million
Let’s look briefly at Corvus Pharmaceuticals Inc. (CRVS) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 11 October was 53.57% to suggest the stock is trending Neutral, with historical volatility in this time period at 157.42%.
The stock’s 5-day moving average is $4.85, reflecting a +10.62% or $0.51 change from its current price. CRVS is currently trading +113.25% above its 20-day SMA, +106.61% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by +154.07% and +34.43% respectively.
Stochastic %K and %D was 12.11% and 14.58% and the average true range (ATR) pointed at 0.79. The RSI (14) points at 55.33%, while the 14-day stochastic is at 20.62% with the period’s ATR at 0.77. The stock’s 9-day MACD Oscillator is pointing at -0.04 and -0.82 on the 14-day charts.
In the most recent analyst report for Corvus Pharmaceuticals Inc. (NASDAQ: CRVS), Cantor Fitzgerald launched coverage with an Overweight rating. Analysts offering their rating for CRVS stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate CRVS as a “sell,”, while 1 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 3 have offered a “buy” rating.
What is CRVS’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $3.50 and a high of $6.00, with their median price target at $5.50. Looking at these predictions, the average price target given by analysts is for Corvus Pharmaceuticals Inc. (CRVS) stock is $5.13.